Developer of novel cancer treatments designed to target DNA damage response. The company's treatments focus on developing therapies through Deoxyribonucleic Acid damage response pathways to help mutations to their DNA so that they can evolve, enabling physicians to selectively kill cancer cells through a concept known as synthetic lethality.